DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Comment by joelouon Dec 07, 2018 8:05pm

63 Views

Post# 29085634

RE:RE:RE:RE:RE:RE:RE:DMA On Watch Territory

Winner. Absolutely not! And yes I did buy today... averaging down...1000 at 4.90 .. obviously bought too early... my life story.. with that being said, I do believe DMA has something that will reward shareholders in the future.. and for the record, I’m disappointed with how this deal went down and have had many conversations with management regarding this transaction... certainly not impressed! Long time shareholder wealth has recently been knocked down —- big time!
lets hope Mr. Pauls has an ace up his skeeve!

Bullboard Posts

Anaergia expands relationship with PepsiCo